Antipsychotics for Amphetamine Psychosis. A Systematic Review

an article by  Dimy Fluyau (Emory University, Atlanta, USA), Paroma Mitra (NYU, New York, USA) and Kervens Lorthe (Miami Regional University, Miami Springs, USA) published in frontiers in Psychiatry (15 October 2019)

Background

Among individuals experiencing amphetamine psychosis, it may be difficult to rule out schizophrenia.
The use of antipsychotics for the treatment of amphetamine psychosis is sparse due to possible side effects.
Some arguments disfavor their use, stating that the psychotic episode is self-limited.
Without treatment, some individuals may not fully recover from the psychosis and may develop full-blown psychosis, emotional, and cognitive disturbance.
This review aims to investigate the clinical benefits and risks of antipsychotics for the treatment of amphetamine psychosis.

Methods

Electronic search on trials on antipsychotic drugs for amphetamine psychosis from their inception to November 2018 was conducted in PubMed, Scopus, Google Scholar, EBSCOhost, ProQuest, Cochrane Review Database, Medline Ovid, and EMBASE following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines.
The Cochrane risk-of-bias tool assessed the risk of bias, the methodological quality of individual trials was assessed by the Oxford Quality Scoring System, and the quality of evidence for recommendations was judged by the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE).
The results were synthesized qualitatively and quantitatively.

Results

The investigation of six randomized controlled trials of 314 participants showed that aripiprazole, haloperidol, quetiapine, olanzapine, and risperidone were able to reduce or control the psychotic episode (positive and negative symptoms) induced by amphetamine use with no adverse event.
Although the side-effect profile of these agents varied, no drug was clinically superior to others.

Conclusions

This review suggests that antipsychotics seem to be efficacious for amphetamine psychosis on both positive and negative symptoms.
Practitioners need to tailor their use based on risks for side effects individually.

Full text (PDF 14pp)

Please note:
This source produces information for practitioners but sometimes, as now, contains something which I think is of more general interest.

---